Lorlatinib
| Use attributes for filter ! | |
| Bioavailability | 81% |
|---|---|
| Formula | C21H19FN6O2 |
| Trade name | Lorbrena, Lorviqua |
| Other names | PF-6463922 |
| ATC code | L01XE44 (WHO) |
| Elimination half-life | 24 hrs (single dose) |
| Music groups | Brigatinib |
| Alectinib | |
| Ceritinib | |
| Crizotinib | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2951232 |
About Lorlatinib
Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer drug developed by Pfizer. It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer.
